Oprah’s flip on weight loss drugs is a sign of what’s to come for the ‘Ozempic trade’ in 2024

Oprah’s flip on weight loss drugs is a sign of what’s to come for the ‘Ozempic trade’ in 2024

For many struggling with obesity, new medications have been “a gift,” as Oprah Winfrey recently described it in declaring she was “done with the shaming.” Investors in drug manufacturers Novo Nordisk and Eli Lilly might use the same term for the returns they’ve realized over the past year. U.S.-listed shares of Novo Nordisk, the maker…

AI, wearables and more — these markets are booming as the world ages

AI, wearables and more — these markets are booming as the world ages

The world is aging rapidly, and there are more and more ways to invest in this theme. Shams Afzal, managing director at Carnegie Investment Counsel, noted that 17% of the U.S. population is now over the age of 65, and that proportion is expected to grow higher. And the demographics of that age group is…

Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch

Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch

Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. As these new therapies begin treating patients, some investors see better times ahead next year. “We’ve seen a lot of innovation,” Dan Lyons, portfolio manager on the health-care team at Janus Henderson, said, explaining that he is bullish on 2024 because…

Reckitt Benckiser unit recalls possibly contaminated baby formula powder, FDA says

Reckitt Benckiser unit recalls possibly contaminated baby formula powder, FDA says

Reckitt/Mead Johnson Nutrition has voluntarily recalled certain Nutramigen Hypoallergenic Infant Formula Powder products due to possible Cronobacter sakazakii contamination. Courtesy: Reckitt/Mead Johnson Baby formula maker Reckitt Benckiser’s Mead Johnson Nutrition has voluntarily chosen to recall certain batches of baby formula powder due to possible bacterial contamination, according to the U.S. Food and Drug Administration. The…

Moderna stock jumps after Oppenheimer upgrade on pipeline potential

Moderna stock jumps after Oppenheimer upgrade on pipeline potential

Artur Widak | Nurphoto | Getty Images Shares of Moderna closed more than 13% higher on Tuesday after Oppenheimer upgraded the stock to “outperform,” saying the Covid vaccine maker could market five products by 2026. The upgrade follows a dismal 2023 for Moderna, whose only commercially available product is its Covid shot. The company’s stock…

End of content

End of content